Score Overview
Explore the 2021 public Archive ranking →
Where Immuneering Corp has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. IMRX does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-21 | $ 3.74 | — |
1 Year2025-10-21 | $ 5.85 | -36.07% |
5 Years2021-10-21 | $ 26.12 | -85.68% |
All Time2021-07-30 | $ 17.59 | -78.74% |
| Period | Last Price2026-10-21 | 1 Year2025-10-21 | 5 Years2021-10-21 | All Time2021-07-30 |
|---|---|---|---|---|
| Price | $ 3.74 | $ 5.85 | $ 26.12 | $ 17.59 |
| Return | — | -36.07% | -85.68% | -78.74% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 360.96K | -$ 57M | $ 149M |
| 2025 | $ 0.00 | -$ 56M | $ 172M |
| 2024 | $ 0.00 | -$ 61M | $ 36M |
| 2023 | -$ 53M | $ 85M | |
| 2022 | $ 316.95K | -$ 50M | $ 105M |
| IPO2021 | $ 2M | -$ 33M | $ 149M |
Immuneering Corp fundamental performance
Between 2021 and 2025, revenue declined from $ 2M to $ 0.00 and net income went from -$ 33M to -$ 56M. Revenue increased in 33% of the years measured; net income in 20%.
Immuneering Corp currently holds a 5-year HDB Score of 2.2 out of 10. How the HDB Score is calculated.
Membership
Explore IMRX with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,118 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
Explore other companies
Creative Medical Technology Holdings IncCELZ· revenue grew in 40% of years
SIGA Technologies IncSIGA· revenue grew in 20% of years
Zhongchao IncZCMD· revenue grew in 40% of years
Aptevo Therapeutics IncAPVO· revenue grew in 0% of years
Milestone Pharmaceuticals IncMIST· revenue grew in 40% of years
